TY - JOUR
TI - p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients with Borderline/Mild Cytology in Cervical Cancer Screening
AU - Magkana, M.
AU - Mentzelopoulou, P.
AU - Magkana, E.
AU - Pampanos, A.
AU - Vrachnis, N.
AU - Kalafati, E.
AU - Daskalakis, G.
AU - Domali, E.
AU - Thomakos, N.
AU - Rodolakis, A.
AU - Anagnou, N.P.
AU - Pappa, K.I.
JO - ANTICANCER RESEARCH
PY - 2022
VL - 42
TODO - 5
SP - 2599-2606
PB - International Institute of Anticancer Research
SN - 0250-1291
TODO - 10.21873/anticanres.15738
TODO - cyclin dependent kinase inhibitor 2A;  Ki 67 antigen, early cancer diagnosis;  female;  human;  papillomavirus infection;  risk assessment;  staining;  uterine cervix carcinoma in situ;  uterine cervix tumor, Cervical Intraepithelial Neoplasia;  Cyclin-Dependent Kinase Inhibitor p16;  Early Detection of Cancer;  Female;  Humans;  Ki-67 Antigen;  Papillomavirus Infections;  Risk Assessment;  Staining and Labeling;  Uterine Cervical Neoplasms
TODO - Background/Aim: To evaluate p16/Ki-67 dual-staining performance for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in the management of women with minor cervical abnormalities. Patients and Methods: All 759 enrolled patients were tested for cytology, high-risk human papillomavirus (HR-HPV) and dual p16/Ki-67 staining. Results: Positivity rates for HR-HPV and dual staining increased as dysplasia was worsened from non-CIN (37.6% and 0%) to CIN1 (62.5% and 1.6%) and CIN2+ (98.7% and 97.3%), respectively. HPV18 and HPV16 exhibited the highest odds ratios (53.16 and 11.31) in the CIN2+ group. Both p16/Ki-67 dual staining and HR-HPV presented similar sensitivities (97.3% and 98.7%, respectively) for CIN2+ detection. Dual staining specificity, however, was 99.3%, significantly higher compared to HR-HPV testing (52.2%). The utility of dual staining was evaluated in different screening strategies and appeared to reduce the number of colposcopies required for the detection of CIN2+ cases. Conclusion: p16/Ki-67 dual-staining cytology is a surrogate triage biomarker in cytology-based screening programs, with high performance for efficient risk stratification of women with mild cervical abnormalities. © 2022 International Institute of Anticancer Research. All rights reserved.
ER -